ANTITHROMBOTIC THERAPY IN CANCER PATIENTS

A. V. Vorobev; A. M. Chabrov; A. A. Savchenko; A. D. Makatsariya

doi:10.17749/2313-7347.2015.10.1.026-037

ANTITHROMBOTIC THERAPY IN CANCER PATIENTS

A. V. Vorobev, A. M. Chabrov, A. A. Savchenko, A. D. Makatsariya

https://doi.org/10.17749/2313-7347.2015.10.1.026-037

Full Text:

PDF (Rus)

Abstract

The article describes the main anticoagulant drugs used in cancer patients, taking into consideration pathogenetic aspects of hypercoagulation status in cancer patients: oral anticoagulants, heparin drugs, selective inhibitors of Xa factor. The basic advantages of low molecular weight heparin compared with unfractioned heparin. The comparison of low-molecular weight heparin drugs, their generics and biosimilar drugs is surveyed. Reviewed recommendations for the prevention of thrombotic complications in cancer patients. Overviewed the possible complications of heparin therapy and methods of prevention.

Keywords

Low-molecular weight heparin, oral anticoagulants, heparin-indused thrombocytopenia, thrombosis prophylaxis, anti- Xa drugs

About the Authors

A. V. Vorobev

First Moscow State Medical Sechenov University of the Ministry of Health Russian Federation
Russian Federation

MD, Ph.D., Associate Professor, Department of Obstetrics and Gynecology, Faculty of Medical and Preventive Medicine First Moscow Medical Sechenov University. Address: ul. Zemlyanoy Val, 62, p. 1, Moscow, Russia, 109004. Tel.: +7(495)7885840

A. M. Chabrov

Cancer clinical dispensary №1 Department of Health of Moscow
Russian Federation

MD, Ph.D., head of gynecological department Clinical Oncological Dispensary №1 Moscow Health Department. Address: ul. Volochaevskaya, 36, Moscow, Russia, 109033

A. A. Savchenko

Cancer clinical dispensary №1 Department of Health of Moscow
Russian Federation

Ph.D., gynecological department Clinical Oncological Dispensary №1 Moscow Health Department. Address: ul. Volochaevskaya, 36, Moscow, Russia, 109033

A. D. Makatsariya

First Moscow State Medical Sechenov University of the Ministry of Health Russian Federation
Russian Federation

MD, corresponding member of the Russian Academy of Sciences, Professor, Head of the Department of Obstetrics and Gynecology, Faculty of Medical and Preventive, First Moscow State Medical Sechenov University. Address: ul. Trubetskaya, 8, str. 2, Moskva, Russia, 119048. Tel.: +7(495)7885840

References

1. Vorobev A.V. Voprosy akusherstva, ginekologii i perinatologii. 2008; 2 (7): 18-25.

2. Makatsariya A.D., Vorob'ev A.V., Chabrov A.M. Value assessment of thrombophilia markers during chemotherapy and radiation therapy in cancer patients. Materials of the Russian Medical Forum – 2006 "Fundamental science and practice", 18-20 October 2006 [Znachenie otsenki markerov trombofilii pri provedenii khimio- i luchevoi terapii u onkologicheskikh bol'nykh. Materialy Rossiiskogo Meditsinskom Forume – 2006 «Fundamental'naya nauka i praktika», 18-20 oktyabrya 2006 g (in Russian)].

3. Makatsariya A.D., Vorob'ev A.V., Bitsadze V.O. Malignancies, thrombophilia, thrombosis [Zlokachestvennye novoobrazovaniya, trombofiliya, trombozy (in Russian)]. Moscow. 2008; 650 s.

4. Makatsariya A.D. et al. Thrombohemorrhagic complications in obstetric practice. Guidelines for doctors under the editorship of AD Makatsariya [Trombogemorragicheskie oslozhneniya v akushersko-ginekologicheskoi praktike. Rukovodstvo dlya vrachei pod redaktsiei A.D. Makatsariya (in Russian)]. Moscow. 2011.

5. The Russian clinical recommendations for diagnosis, treatment and prevention of venous thromboembolic events. Association of Phlebology Russia, Russian Society of Surgeons [Rossiiskie klinicheskie rekomendatsii po diagnostike, lecheniyu i profilaktike venoznykh tromboembolicheskikh oslozhnenii. Assotsiatsiya flebologov Rossii, Vserossiiskoe obshchestvo khirurgov (in Russian)]. Moscow. 2010.

6. Tsyb A.F., Sushkevich G.N., Baluda M.V., Vorob'ev A.V., Chabrov A.M. Principles of prevention of thrombotic complications in patients with cancer (solid tumors). Manual for physicians [Printsipy profilaktiki tromboticheskikh oslozhnenii u onkologicheskikh bol'nykh (solidnye obrazovaniya). Posobie dlya vrachei (in Russian)]. Obninsk. 2008; 42 s.

7. Shilova A.N., Lazarev A.F., Vorob'ev P.A., Barkagan Z.S., Khodorenko S.A., Kotovshchikova E.F., Momot A.P., Buevich E.I. Sibirskii onkologicheskii zhurnal. 2008; 3: 74-76.

8. Agnes Y.Y. Lee, M.D., Mark N. Levine, M.D., Ross I. Baker, M.D., Chris Bowden, M.D., Ajay K. Kakkar, M.B., Martin Prins, M.D., Frederick R. Rickles, M.D., Jim A. Julian, M.Math., Susan Haley, B.Sc., Michael J. Kovacs, M.D., Michael Gent. Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer. N Engl J Med. 2003; 349: 146-153.

9. Bogenrieder T., Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene. 2003; 22: 6524-36.

10. David Bergqvist, Giancarlo Agnelli, Alexander T. Cohen, Amiram Eldor, Paul E. Nilsson, Anne Le Moigne-Amrani, Flavia Dietrich-Neto F. ENOXACAN II Investigators. Duration of Prophylaxis against Venous Thromboembolism with Enoxaparin after Surgery for Cancer. N Engl J Med. 2002; 346: 975-980.

11. Drugs. Establishing Active Ingredient Sameness for Generic Enoxaparin Sodium, a Low Molecular Weight Heparin. 2010 July 28.

12. Donati M.B., A. Falanga: Patogenetic Mechanisms of Thrombosis in Malignancy. Acta Haematol. 2001; 106: 18-24.

13. EMEA. Guidelines on Clinical and Non-Clinical Development of Medicinal Products Containing Low-Molecular-Weight Heparins. London: European Medical Agency; 2009. EMEA/CHMP/BMWP/11826407enfin.pdf. 2010 July 29.

14. Falanga A., Marchetti M., Vignoli A. Pathogenesis of thrombosis in cancer. Thromb and cancer. 2004; 30: 11-23.

15. FDA News Release. fda.gov/NewsEvents/Newsroorn/PressAnnouncements/ucm220092.hm.

16. Accessed: 23.07.2015.

17. Gray E., Mulloy B., Barrowcliffe T.W. Heparin and low-molecularweight heparin. Thromb Haemost. 2008; 99: 807-18.

18. Gray E., Rigsby P., Behr-Gross M.E. Collaborative study to establish the lowmolecular- mass heparin for assay – European Pharmacopoeia Biological Reference Preparation. Pharmeuropa Bio. 2004; 1: 59-76.

19. Guerrini M., Guglieri S., Naggi A., Sasisekharan R., Torri G. Low molecular weight heparins: structural differentiation by bidimensional nuclear magnetic resonance spectroscopy. Semin Thromb Hemost. 2007; 33: 478-87.

20. Harenberg J., Kakkar A., Bergqvist D. et al. On behalf of the Subcommittee on Control of Anticoagulalion of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemoslasis. Recommendations on biosimiliar lowmolecular- weight heparins. J Thromb Haemost. 2009; 7 (7): 1222-1225.

21. Hirsh J., Warkentin T.E., Shaughnessy S.G. et al: Heparin and lowmolecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001; 119: Suppl. 1: 64-94.

22. Kakkar A.K., Levine M.N., Kadziola Z. et al. Low molecular weight heparin therapy with dalteparin and survival in advanced cancer the Fragmin Advanced Malignancy Outcome Study (FAMOUS). J. Clin. Oncol. 2004; 22 (10): 1944-1948.

23. Kalodiki E., Leon W. SASAT and Task Force on Generic LMWHs. SASAT (South Asian Society on Atherosclerosis and Thrombosis) proposal for regulatory guidelines for generic low molecular weight heparins (LMWHs). Clin Appl Thromb Hemost. 2009; 15 (1): 8-11.

24. Klerk C.P.W., Smorenburg S.M., Otten H.M. et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J. Clin. Oncol. 2005; 23 (10): 2130-2135.

25. Lee AYY. Screening for occult cancer in patients with idiopathic venous thromboembolism. J Thromb Haemost. 2003; 1: 2273-2274.

26. Meyer G., Marjanovic Z., Valcke J. et al. Comparison of low molecular weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer a randomized controlled study. Arch. Intern. Med. 2002; 162 (15): 1729-1735.

27. New Oral Anticoagulants and the Cancer Patient theoncologist.com/article/new-oralanticoagulants-and-cancer-patient.

28. New Anticoagulants: Anti IIa vs Anti Xa-Is One Better? Kenneth A. Bauer MD. Journal of Thrombosis and Thrombolysis. February 2006; 21 (1): 67-72.

29. North American Thrombosis Forum Official Policy Statement regarding the protection of patient safety and patient rights on the matter of follow-on biologies. natfonIine.org/NATFbiologiessta-tement.php. Accessed: 26.07.2010.

30. Prandoni P., Lensing A.W., Piccioli A. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002; 100 (10): 3484-3488.

31. Prandoni P., Falanga A., Piccioli A. Cancer and venous thromboembolism.

32. Lancet Oncol. 2005 Jun; 6 (6): 401-10.

33. Prandoni P., Lensing A.W., Buller H.R. et al. Deep vein thrombosis and the incidence of subsequent symptomatic cancer. N. Engl. J. Med. 1992; 327 (16): 1128-1133.

34. Samama M.M., Gerotziafas G. Comparative Pharmacokinetics of LMWHs. Semin Thromb

35. Hemost. 2000; 26: 31-6.

36. Samama M.M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med. 2000; 160: 3415-20.

37. van Dongen C.J., Mac Gillavry M.R., Prins M.H. Once versus twice daily LMWH for the initial treatment of venous thromboembolism. Cochrane Database Syst. Rev. 2005; 3. Art. № CD003074.

38. WHO 2009. Guidelines on evaluation of similar biotherapeutic products (SBPs). who.int/biologicaIs/areas/biologicaI_thcrapeutic/BIOTHERAPETUTICS_FOR_WEB_22APRIL2010_WI. Accessed: 18.08.2015.

39. Zacharski Leo R. Malignancy as a solid-phase coagulopathy: implications for the etiology, pathogenesis, and treatment of cancer. Seminars in thrombosis and hemostasis. 2003; 29: 239-46.

For citation:

Vorobev A.V., Chabrov A.M., Savchenko A.A., Makatsariya A.D. ANTITHROMBOTIC THERAPY IN CANCER PATIENTS. Obstetrics, Gynecology and Reproduction. 2016;10(1):26-37. (In Russ.) https://doi.org/10.17749/2313-7347.2015.10.1.026-037